IS 1 MG OF ESTRADIOL VALERATE OR 0.625 MG OF CONJUGATED ESTROGENS SUFFICIENT FOR ALL WOMEN TO PREVENT MENOPAUSAL BONE LOSS

被引：4

作者：

DUURSMA, SA

DERAADT, M

RAYMAKERS, JA

HASPELS, AA

机构：

[1] Department of Internal Medicine, Research Group for Bone Metabolism

[2] Department of Gynaecology, University Hospital Utrecht

来源：

GYNECOLOGICAL ENDOCRINOLOGY | 1992年 / 6卷 / 03期

关键词：

BONE MINERAL CONTENT; POSTMENOPAUSAL BONE LOSS; HORMONAL REPLACEMENT THERAPY; CONJUGATED ESTROGENS; ESTRADIOL VALERATE;

D O I：

10.3109/09513599209015556

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Bone mineral content was measured by dual photon absorptiometry in 35 women who needed estrogen replacement therapy but did not want the addition of progestogens because they did not want regular bleeding. A total of 23 women were treated with estradiol valerate 1 mg per day over a mean period of 3.7 years; 12 women received conjugated estrogens 0.625 mg per day over a mean period of 5.3 years. The mean values of bone mineral content in both groups did not change. In the women on estradiol valerate, 61% had a decrease, and in those on conjugated estrogens, 67% had a decrease in bone mineral content. However, the calculated decrease per year was within the limits of the intraindividual reproducibility of the measurements. A difference between two measurements with a decrease of > 1.0 g hydroxyapatite/year over a period of > 3 years is larger than the limits of the intraindividual reproducibility. A decrease in bone mineral content > 1.0 g hydroxyapatite/year over a mean period of 3.98 years, SD 0.35, was observed in six of 23 (26%) of the women on estradiol valerate with a mean decease of 5.28 g hydroxyapatite, SD 0.97. Only one of 12 (8%) of the women on conjugated estrogens had a decrease of 6.1 g hydroxyapatite over a period of 5.2 years. Periodic measurement of bone mineral is recommended in women on estrogen replacement therapy with estradiol valerate 1 mg per day or conjugated estrogens 0.625 mg per day for prevention of postmenopausal bone loss.

引用

页码：205 / 209

页数：5

共 14 条

[1]

Lindsay R., Hart D.M., Aitken J.M., MacDonald E.B., Anderson J.B., Clarke A.C., Long-term prevention of postmenopausal osteoporosis by estrogen, Lancet, 1, pp. 1038-1041, (1976)

[2]

Christiansen C., Christensen M.S., Transbol I., Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy, Lancet, 1, pp. 459-461, (1981)

[3]

Genant H.K., Ettinger B., Gordan G.S., Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy, Ann. Intern. Med., 97, pp. 699-705, (1982)

[4]

Ettinger B., Genant H.K., Cann C.E., Long term estrogen replacement therapy prevents bone loss and fractures, Ann. Intern. Med., 102, pp. 319-324, (1985)

[5]

Hirvonen E., Elliesen J., Schmidt-Gollwittzer K., Comparison of two hormone replacement regimens - influence on lipoproteins and bone mineral content, Maturitas, 12, pp. 127-136, (1990)

[6]

Mandel F.P., Davidson B.J., Erlik Y., Yudd H.L., Medrum D.R., Effects of progestins on bone metabolism in postmenopausal women, J. Reprod. Med., 2, (1982)

[7]

Lindsay R., Skeletal effects of progestins: clinical studies, Int. Proc. J., 1, pp. 199-204, (1989)

[8]

Abdalla H.I., Hart D.M., Lindsay R., Leggatte I., Hooke A., Prevention of bone mineral loss in postmenopausal women by norethisterone, Obstet. Gynecol., 66, pp. 789-792, (1985)

[9]

Prior J.C., Trabecular bone loss is associated with abnormal luteal phase length: endogenous progesterone delivery may be a risk factor for osteoporosis, Int. Proc. J., 1, pp. 70-73, (1989)

[10]

Raymakers J.A., Van Dijke C.F., Hoekstra A., Duursma S.A., Monitoring fluoride therapy in osteoporosis by dual photon absorptiometry, Bone, 8, pp. 143-148, (1987)

← 1 2 →